Sage Therapeutics receives fast track designation for SAGE-718 for the treatment of Huntington’s disease

Sage Therapeutics

15 September 2021 - Sage Therapeutics today announced that the U.S. FDA has granted fast track designation to SAGE-718 for development as a potential treatment for Huntington’s disease,

SAGE-718, Sage’s first in class NMDA receptor PAM and lead neuropsychiatric drug candidate, is in development as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction, potentially including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease.

Read Sage Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track